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CHRONIC HEPATITIS B AND THEIR
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OBJECTIVE: Approximately 700,000 people in Spain
are infected with HBV. The medical costs associated with
chronic HBV have not yet been studied in Spain. This
research aims to estimate the treatment patterns of 
major HBV health states and their associated costs.
METHODS: Resource use patterns were determined by
a panel of physicians caring for HBV patients in three
hospitals using a questionnaire. A review of the literature
on the cost of the disease was also carried out. Average
values of health resource utilisation were computed for
patients with chronic hepatitis B (CHB), compensated
and decompensated cirrhosis (CC and DC), hepatocellu-
lar carcinoma (HC) and liver transplantation (LT). Unit
costs were derived from the Soikos health unit costs data-
base. RESULTS: No variations in clinical practice were
detected among the experts consulted. The estimated
annual cost is €3396 for CHB (€8493 if treated with
antiviral therapy -33% patients- and €850 for patients
without antivirals). Estimated annual cost for CC is
€3997 (€7486 if treated with antiviral therapy -50%
patients- and €510 for patients without antivirals).
Average annual cost of DC (including ascites, bacterial
peritonitis, variceal haemorrhage and hepatic enceph-
alopathy) is €6851. Hepatocellular carcinoma costs
€3,731 annually with few patients receiving chemother-
apy. Liver transplantation was estimated to cost €25,165
for the transplantation phase and €5,770 in the ﬁrst year
post transplant. CONCLUSIONS: The results obtained,
although not fully representative for Spain due to the
small number of hospitals sampled, show that the costs
associated with chronic HBV are signiﬁcant. The most
severe stages such as episodes of decompensated cirrho-
sis and transplantation are the major cost drivers. Adopt-
ing therapies that slow or stop disease progression could
reduce morbidity and mortality and also the cost burden
to the health care system.
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OBJECTIVE: In this study, cost-effectiveness of the 23-
valent pneumococcal vaccination was assessed in Cat-
alonia (Spain). METHODS: Cost-effectiveness was
measured in terms of cost per life year gained (LYG), com-
paring net program costs and effectiveness. The net
program cost was calculated from vaccinating cost less
reduced health care costs from pneumococcal pneumo-
nia. Vaccination costs were calculated taking into account
a price per vaccine of €11.51. Costs and beneﬁts were esti-
mated for the period 1996–2001 using a 5% discount
rate. RESULTS: The cost-effectiveness was €9,023 per
LYG for the universal vaccination of individuals aged >5
years, €113,177 per LYG in individuals aged 5–24 years,
€19,482 per LYG in those aged 25–44 years, €7,123 per
LYG in those aged 45–64 years and €-4,442 per LYG in
those aged >64 years. Results were sensitive to the vaccine
price and efﬁcacy, and the percentage of pneumonias
caused by S. pneumoniae. Multiway sensitivity analysis
showed that, in individuals aged >64 years, the vaccine
was cost-effective for vaccine efﬁcacy >45% when the
percentage of pneumonias caused by S. pneumoniae of
20%, >30% for a percentage of 30% and >25% for a
percentage of 40%, and when efﬁcacy was >30% for the
current price per vaccine, >40% for a price of €15, and
>50% for a price of €20. In individuals aged 45–64 years,
the cost-effectiveness was <€30,000/LYG when vaccine
efﬁcacy was >80% for a percentage of pneumonias
caused by S. pneumoniae of 20%, >60% for a percent-
age of 30% and >40% for a percentage of 40%. The cost-
effectiveness was <€30,000/LYG when efﬁcacy was >30%
for the current price, >50% for a price of €15, and >70%
for a price of €20. CONCLUSION: Results obtained in
this study shows that pneumococcal vaccination should
be a priority preventive intervention in individuals aged
>64 and 45–64 years.
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OBJECTIVE: In order to increase case-detection of
Chlamydia trachomatis (CT) in a multicultural, low-
income and high-CT-prevalence neighbourhood a novel
approach was piloted in collaboration with the pharmacy
of the health centre. The objective of this study is to esti-
mate cost-effectiveness of the approach. METHODS:
During a 2-year period, women aged 15–29yrs. who col-
lected their contraceptives at the pharmacy were offered
CT-test materials. Home-collected urine could be mailed
to the laboratory and the General Practitioner received
the results. RESULTS: Nine percent of respondents were
CT-positive (14% among 15–24yr). There was a strong
association with Surinamese/Antillean background.
Uptake of the programme was low (27%). Net cost per
PID prevented ranged from cost-saving up to €3872 in a
low complication rate scenario. CONCLUSIONS: Faced
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with higher risk, but low participation rates, active case-
detection of CT-infections in “high-prevalence-area’s”
needs a concerted approach of different providers and
community organisations, both in secondary as in pri-
mary prevention. The pharmacist can contribute if proper
liaison is made with primary care providers and/or public
health services for (partner-)treatment, counseling, and
comprehensive sexual health care.
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OBJECTIVE: The UK is a low endemic area for hepati-
tis B virus. Nevertheless, the National Health Service
(NHS) burden of managing the disease and its long term
sequelae is thought to be great. Understanding the extent
of this cost is needed to estimate the budget impact of
adopting therapies that avoid morbidity and mortality.
The purpose of this study is to estimate the resources and
costs associated with major health states of chronic
hepatitis B (CHB). METHODS: Annual health care
resource use was estimated by a panel of expert hepatol-
ogists for patients with chronic active hepatitis B (CAHB),
compensated and decompensated cirrhosis (including
ascites, bacterial peritonitis, variceal haemorrhage and
hepatic encephalopathy), and hepatocellular carcinoma.
Liver transplantation costs were obtained from published
sources and unit costs from NHS-relevant sources.
RESULTS: In the UK 39% of CHB patients receive antivi-
ral therapy. The estimated annual cost is £2503 for
CAHB and £2631 for compensated cirrhosis managed
with antivirals. For patients without antivirals (61%),
annual costs are £547 (CAHB) and £745 (compensated
cirrhosis). Estimated annual cost for decompensated cir-
rhosis is £5842 using a distribution across the possible
manifestations of the disease. Hepatocellular carcinoma
is £6167 annually with less than 25% of patients receiv-
ing chemotherapy. Liver transplantation costs over
£31,000 for the transplantation and £10,700 in the ﬁrst
year post transplant. CONCLUSIONS: The direct
medical costs of CHB are substantial. Slowing or stop-
ping disease progression could reduce the morbidity and
mortality burden on patients and the cost burden for the
NHS.
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OBJECTIVES: To illustrate how value of information
analyses can be used to inform the efﬁcient design of
future research using an updated cost-effectiveness model
of Zanamivir, Oseltamivir and Amantadine versus normal
treatment for persons with inﬂuenza-like-illness (ILI).
METHODS: Systematic review and meta-analysis of evi-
dence relating to the effectiveness in terms of length of
illness, complication rate and adverse event proﬁle for all
three antiviral treatments was used to inform a proba-
bilistic decision model. The incremental cost per QALY
was estimated and Monte Carlo simulation used to 
generate a cost-effectiveness acceptability curve. The
expected value of perfect information (EVPI) was calcu-
lated. Partial EVPI for each of the uncertain parameters
in the model was calculated using a two-level simulation
approach. This same approach was used to calculate the
expected value of sample information (EVSI) for a
number of different research designs. RESULTS: For
healthy adults the incremental cost per QALY of Aman-
tadine compared to no treatment is approximately £13k.
The ICER for Oseltamivir compared to Amantadine is
approximately £42k. Oseltamivir dominates Zanamivir.
However, these estimates are extremely uncertain, as
reﬂected in the cost effectiveness acceptability curve.
Value of information analyses indicate ﬁrstly, the value of
that uncertainty within the model and secondly, the most
efﬁcient design for future research aimed at reducing that
uncertainty. CONCLUSIONS: This paper illustrates the
application of recent advances in value of information
methods to the policy relevant issue of inﬂuenza treat-
ments. It indicates that improved knowledge of the pro-
portion of individuals that actually have inﬂuenza and the
QALY values associated with inﬂuenza are two variables
of particular value for future research.
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OBJECTIVES: Although pertussis is thought of most
often as a disease of childhood, it can occur in all ages.
It has been reported that pertussis in adolescents and
adults is on the rise in some Western countries. The goal
of this analysis was to determine the age distribution of
pertussis cases in hospitals in Germany, as well the length
of stay (LOS) and related costs per stay. METHODS:
Hospital discharge data by age group for pertussis cases
(ICD-9 codes: 033.0–033.9) admitted in 1999, and 2002
per diem hospital costs were obtained from the Federal
Statistical Bureau in Germany. These data were used to
develop LOS and inpatient hospital costs by age group
for a pertussis-related hospitalization. Cost estimates are
reported in €2002. RESULTS: Of the 1118 pertussis cases
identiﬁed, 52% were female. Ages ranged from infant to
75+ years. Those <1 year comprised 65% of admissions;
9% were between 1–5 years; 19% were between 6–15
years; 2% were aged 16–25 and 5% were 26 years and
